Search
for
Sort by
Research 31–60 of 201
- A novel therapeutic paradigm for patients with extensive alopecia areata
- Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims
- Elevated fasting insulin is associated with cardiovascular and metabolic risk in women with polycystic ovary syndrome
- A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
- Cardiodermatology: the heart of the connection between the skin and cardiovascular disease
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- CD201+ fascia progenitors choreograph injury repair
- Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives
- Steroid Hormones
- Management of Toxicities of Targeted Therapies
- Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells
- The role of janus kinases in the treatment of autoimmune skin diseases
- Scaffolds for epithelial and hair follicle regeneration
- Industry update: the latest developments in the field of therapeutic delivery, July 2018
- STUDIES ON THE ANTIMICROBIAL ACTIVITY OF EVOLVULUS ALSINOIDES, MURRAYA KOENIGII, LAWSONIA INERMIS, HIBISCUS ROSA-SINENSIS, AZADIRACHTA INDICA AGAINST MALASSEZIA FURFUR USING FRACTIONAL FACTORIAL DESIGN
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- From a stem-cell–centered to a niche-centered view: the core role of collagen networks in hair loss and hair follicle miniaturization
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Bhangra: Therapeutic and Pharmacological Actions in Shayb (Premature Greying of Hair)
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey
- Farmácia Militar do Laboratório Nacional do Medicamento, Porto e Serviços Farmacêuticos do Centro Hospitalar Universitário do Porto (Hospital de Santo António), EPE, Porto
- Dermal EZH2 simultaneously orchestrates dermal differentiation and epidermal proliferation during murine skin development
- Program and Abstract of 16th APALMS 2018